Compare ACADIA Pharmaceuticals Inc. (ACAD) vs GraniteShares 2x Long COIN Daily ETF (CONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs GraniteShares 2x Long COIN Daily ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.44 (market cap $5.07B), while GraniteShares 2x Long COIN Daily ETF trades at $4.11. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | CONL | |
|---|---|---|
Market Cap | $5.07B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $29.41 | $48.70 |
52-Week Low | $20.06 | $3.93 |
Enterprise Value | $4.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
CONL, the GraniteShares 2x Long COIN Daily ETF, trades at $4.175, up 2.08% on the day, but remains in a pronounced bearish technical trend with all moving averages signaling sell. The ETF is designed to deliver twice the daily return of Coinbase stock (COIN), which has experienced significant volatility. Recent news highlights substantial losses, with CONL down 67% year-to-date as of June 2026, illustrating the high-risk nature of leveraged products.
The outlook is highly speculative and carries extreme risk due to the ETF's daily reset leverage, which can lead to rapid value erosion during volatile periods. Investment opportunity is limited to aggressive, short-term traders who can manage the volatility tax. The primary risk is the structural decay associated with daily rebalancing in a choppy market for the underlying asset.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About GraniteShares 2x Long COIN Daily ETF
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →
